Literature DB >> 11702295

Verrucas. Guidelines for management.

J A Leman1, E C Benton.   

Abstract

Most people will experience infection with human papilloma virus (HPV) at some point in their life. Diagnosis, based on clinical examination, is usually straight forward. Treatment can, however, be challenging. Indications for treatment include pain, interference with function, cosmetic embarrassment, and risk of malignancy. Clearance rates are highest in young, healthy individuals with short duration of infection. Treatment may be with destructive agents (keratolytics, cryotherapy, curettage and cautery, laser, photodynamic therapy), with antimitotic agents (podophyllin, bleomycin, retinoids), with immune stimulants (topical sensitizers, cimetidine), or with topical virucidal agents [formaldehyde (formalin), glutaral (gluteraldehyde)]. As yet, there is no single totally effective treatment for viral warts. Some patients may choose to leave their warts untreated until spontaneous resolution. In those who seek intervention, simple, well tolerated therapies should be chosen initially in preference to more complicated, potentially harmful agents. It is likely that future research will be directed to developing an antiviral agent specific for HPV which would be safe, effective and not prohibitively expensive.

Entities:  

Mesh:

Year:  2000        PMID: 11702295     DOI: 10.2165/00128071-200001030-00001

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  10 in total

1.  Glycolic acid 15% plus salicylic acid 2%: a new therapeutic pearl for facial flat warts.

Authors:  Carmen Rodríguez-Cerdeira; Elena Sánchez-Blanco
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

2.  Bumps on the hand.

Authors:  Jennifer Clay Cather
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-07

Review 3.  An armamentarium of wart treatments.

Authors:  Michelle M Lipke
Journal:  Clin Med Res       Date:  2006-12

4.  Genital and extra-genital warts increase the risk of asymptomatic genital human papillomavirus infection in men.

Authors:  Brenda Y Hernandez; Yurii B Shvetsov; Marc T Goodman; Lynne R Wilkens; Pamela J Thompson; Xuemei Zhu; James Tom; Lily Ning
Journal:  Sex Transm Infect       Date:  2011-05-20       Impact factor: 3.519

Review 5.  Tumors of the hand.

Authors:  Andreas F Mavrogenis; Georgios N Panagopoulos; Andrea Angelini; Jan Lesenský; Christos Vottis; Panayiotis D Megaloikonomos; Zinon T Kokkalis; Vasilios Kontogeorgakos; Pietro Ruggieri; Panayiotis J Papagelopoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-06-05

Review 6.  Recurrent respiratory papillomatosis: an overview.

Authors:  Qingliang Xue; Haitao Wang; Jianxin Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-28       Impact factor: 3.267

7.  A Study to Evaluate the Role of Intradermal and Intralesional Measles, Mumps, Rubella (MMR) Vaccine in Treatment of Common Warts.

Authors:  Pragya Gupta; Geeta Ram Tegta; G K Verma; Abhishek Gupta; Mudita Gupta; Shikha Sharma
Journal:  Indian Dermatol Online J       Date:  2020-07-13

Review 8.  Immunomodulators in warts: Unexplored or ineffective?

Authors:  Surabhi Sinha; Vineet Relhan; Vijay K Garg
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

9.  Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts.

Authors:  Scott Guenthner; Wendy McFalda; Melita Tate; Kimberly Eads; Jayson Rieger; David K Glover; Cynthia Willson; Pamela Rumney; Ted Rosen; Jennifer Andres; Melissa Olivadoti
Journal:  Am J Clin Dermatol       Date:  2021-09-13       Impact factor: 7.403

10.  Intralesional Injection of the Measles-Mumps-Rubella Vaccine into Resistant Palmoplantar Warts: A Randomized Controlled Trial.

Authors:  Mohammad Sadegh Rezai; Hiva Ghasempouri; Ozra Asqary Marzidareh; Jamshid Yazdani Cherati; Ghasem Rahmatpour Rokni
Journal:  Iran J Med Sci       Date:  2019-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.